Biotech News

Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update

Spero Therapeutics (SPRO)Spero Therapeutics2026-06-25 13:46 ESTFDA / regulatory

SPA Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023

Sath Shukla Became President and CEO, Effective August 1

Conference call and webcast...

Open original release

Related news

SPROSpero Therapeutics2026-07-14 11:02 EST

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

SPROSpero Therapeutics2026-06-25 13:46 EST

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

SPROSpero Therapeutics2026-06-25 13:46 EST

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-06-25 13:46 EST

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

SPROSpero Therapeutics2026-06-25 13:46 EST

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

SPROSpero Therapeutics2026-06-25 13:46 EST

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

SPROSpero Therapeutics2026-06-25 13:46 EST

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

SPROSpero Therapeutics2026-06-25 13:46 EST

Spero Therapeutics to Present at Upcoming November Investor Conferences

SPROSpero Therapeutics2026-06-25 13:46 EST

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

SPROSpero Therapeutics2026-06-25 13:46 EST

Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update

View all latest news

Spero Therapeutics

Spero Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

SPROZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

SPROSpero Therapeutics2026-07-14 11:02 EST

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

SPROZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

SPROBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

SPROGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

Stock data

Close: 2.10 USD
Market cap: 121.59M USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States